BioVersys Highlights and Financials for H1 2025

BioVersys AG, a biopharmaceutical company based in Basel, Switzerland, released its corporate highlights and key financials for the first half of 2025. A successful IPO on the SIX Swiss Exchange in February raised CHF 76.7 million, significantly boosting cash reserves to CHF 92.1 million. The company remains funded through 2028.

Key developments include BV100's successful Phase 2 trial results for Ventilator-Associated Bacterial Pneumonia, with Phase 3 set to initiate later in 2025. Alpibectir enters Phase 2 trial for pulmonary Tuberculosis with partner GSK, aiming for top-line data by Q2 2026. Additionally, BioVersys and Shionogi commenced a collaboration on BV500 for non-tuberculous mycobacteria infections.

Financially, BioVersys reported a net loss of CHF 11.0 million, with expenses primarily in R&D. Improved financial guidance forecasts a CHF 29 million operating loss by year-end, with cash equivalents expected to be CHF 78 million.